Arbutus Biopharma Corp Increase (Decrease) in Deferred Liabilities
Arbutus Biopharma Corp (ABUS) reported Increase (Decrease) in Deferred Liabilities of $0 for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2018-11-07
- Arbutus Biopharma Corp increase (decrease) in deferred liabilities for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp increase (decrease) in deferred liabilities for the quarter ending 2017-09-30 was $744.00K.
- Arbutus Biopharma Corp increase (decrease) in deferred liabilities for the quarter ending 2014-06-30 was $57.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-09-30 | $744.00K 10-Q · filed 2018-11-07 | $744.00K 10-Q · filed 2018-11-07 | |
| 2014-06-30 | $57.00K 10-Q · filed 2015-08-07 | $112.00K 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |